Zetia vs Repatha: Head-to-Head Efficacy Comparison

How These Two Drugs Lower LDL Cholesterol

Ezetimibe and evolocumab reduce low-density lipoprotein (LDL) through completely different biological pathways. That distinction explains much of the gap in their potency, cost, and clinical positioning.

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting dietary and biliary cholesterol absorption by roughly 50% 1. The liver compensates by upregulating LDL receptors, which pulls circulating LDL out of the bloodstream. When added to a statin, ezetimibe typically lowers LDL by an additional 23% to 24%. The drug is taken as a single 10 mg oral tablet daily, and generic versions are widely available for as little as $10 to $20 per month at most pharmacies.

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally degrades LDL receptors on hepatocytes. By blocking this degradation, evolocumab dramatically increases the number of LDL receptors available to clear LDL from the blood 2. The result is a 59% to 60% reduction in LDL on top of statin therapy. Patients self-inject 140 mg every two weeks or 420 mg monthly using a prefilled autoinjector. The list price remains above $5,800 per year, though manufacturer copay programs and payer negotiations have brought out-of-pocket costs down for some patients.

Both drugs have favorable safety profiles. Ezetimibe's most common side effects are upper respiratory infection, diarrhea, and arthralgia 1. Evolocumab's are nasopharyngitis, injection-site reactions, and back pain 2.

IMPROVE-IT: The Landmark Trial for Ezetimibe

The IMPROVE-IT trial established ezetimibe as the first non-statin drug proven to reduce cardiovascular events when added to a statin. The trial enrolled 18,144 patients who had been hospitalized for acute coronary syndrome (ACS) within the prior 10 days 1.

Patients received either simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. Over a median follow-up of 6 years, the combination group achieved a mean LDL of 53.7 mg/dL compared with 69.5 mg/dL in the simvastatin-only group. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the ezetimibe/simvastatin group versus 34.7% of the simvastatin-only group, a 6.4% relative risk reduction (HR 0.936, 95% CI 0.89-0.99, P=0.016) 1.

That absolute difference of 2 percentage points over 7 years may seem modest. But the trial confirmed a principle that reshaped lipid management: LDL reduction with a non-statin agent does translate to fewer heart attacks and strokes, consistent with the "lower is better" hypothesis. Dr. Christopher Cannon, the lead investigator, stated: "This validates the concept that lowering LDL cholesterol by any mechanism reduces cardiovascular events" 1.

Subgroup analyses revealed that patients with diabetes (27% of the trial population) derived the greatest benefit, with a number needed to treat (NNT) of approximately 50 over 7 years. The safety profile was reassuring. There were no significant increases in myopathy, hepatotoxicity, gallbladder events, or cancer 1.

FOURIER: The Case for Evolocumab

The FOURIER trial tested evolocumab in a broader, higher-risk population: 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already receiving moderate- or high-intensity statin therapy 2.

At 48 weeks, evolocumab reduced LDL by 59% from a median baseline of 92 mg/dL, bringing median LDL to 30 mg/dL. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001). The key secondary endpoint (cardiovascular death, MI, or stroke) was reduced by 20% (HR 0.80, 95% CI 0.73-0.88, P<0.001) 2.

These results were striking. Dr. Marc Sabatine, the principal investigator, noted: "Patients achieved LDL levels well below 40 mg/dL, and the benefit continued to accrue over time without any safety signal" 2.

The median follow-up was 2.2 years, shorter than IMPROVE-IT's 6 years. Extended open-label data from FOURIER-OLE (presented at ACC 2022 and published in Circulation) showed that the cardiovascular benefit continued to grow out to 5 years, with a 15% reduction in cardiovascular death that was not seen in the initial 2.2-year window 3. No new safety concerns emerged, and there was no signal of neurocognitive harm even at very low LDL levels.

Cross-Trial Comparison: Putting the Numbers Side by Side

No randomized controlled trial has directly compared ezetimibe with evolocumab. Cross-trial comparisons carry inherent limitations because patient populations, follow-up durations, background therapies, and endpoint definitions differ. Still, the available data allow clinicians to draw reasonable inferences.

LDL lowering tells the clearest story. Ezetimibe added to a statin produces roughly 24% further LDL reduction. Evolocumab produces roughly 59%. On an absolute basis, IMPROVE-IT moved median LDL from 69.9 mg/dL to 53.7 mg/dL (a drop of 16 mg/dL), while FOURIER moved median LDL from 92 mg/dL to 30 mg/dL (a drop of 62 mg/dL) 1 2.

For MACE reduction, IMPROVE-IT showed a 6.4% relative risk reduction over 6 years, and FOURIER showed a 15% relative risk reduction over 2.2 years. Extrapolating FOURIER's benefit to 6 years using the open-label extension data suggests the gap widens further 3.

The Cholesterol Treatment Trialists' (CTT) meta-analysis framework offers a useful benchmark. The CTT collaboration demonstrated that each 1 mmol/L (38.7 mg/dL) reduction in LDL produces roughly a 22% proportional reduction in major vascular events over 5 years 4. Both ezetimibe and evolocumab appear to follow this linear relationship, which suggests the difference in cardiovascular benefit is primarily driven by the magnitude of LDL lowering rather than any drug-specific "pleiotropic" effect.

This is not a close contest on raw potency. Evolocumab is roughly 2.5 times more effective at lowering LDL than ezetimibe. But potency alone does not determine which drug is right for a given patient.

Who Should Get Ezetimibe First, and Who Needs Evolocumab

The 2018 ACC/AHA Cholesterol Guideline and the 2022 ACC Expert Consensus Decision Pathway position ezetimibe as the preferred second-line add-on after maximally tolerated statin therapy for patients not at LDL goal 5. PCSK9 inhibitors like evolocumab are reserved for patients who remain above their LDL threshold after a statin plus ezetimibe, or who have very high-risk features such as multiple MACE events.

This stepped approach makes clinical sense. A patient with ASCVD whose LDL is 85 mg/dL on rosuvastatin 20 mg and who needs to get below 70 mg/dL can achieve that with the addition of ezetimibe alone. Generic ezetimibe costs under $20 per month. Prescribing evolocumab for a 15 mg/dL gap that ezetimibe can close would expose the patient to unnecessary cost and injectable therapy.

Consider a different patient: someone with heterozygous familial hypercholesterolemia (HeFH) whose LDL is 145 mg/dL on maximum-dose rosuvastatin plus ezetimibe. This patient needs roughly 50% additional LDL reduction to approach 70 mg/dL. Ezetimibe is already on board. Evolocumab is the evidence-based next step and will likely achieve the target 6.

For patients with recent ACS (within 1 to 12 months) and LDL still above 70 mg/dL despite statin plus ezetimibe, the 2022 ACC pathway recommends early consideration of a PCSK9 inhibitor given the higher event rate in the first year post-ACS 5.

The decision also depends on patient preference. Some patients strongly prefer oral medications over injections. Others, particularly those with statin intolerance, may tolerate evolocumab monotherapy better than statin rechallenge.

Cost, Access, and Insurance Realities

Cost is a defining difference between these two drugs. Generic ezetimibe 10 mg is one of the most affordable branded-to-generic conversions in cardiology, with GoodRx prices often between $8 and $25 for a 30-day supply 7. Most commercial and Medicare Part D plans cover it without prior authorization.

Evolocumab carries a net price that has dropped from its original $14,100 per year in 2015 to approximately $5,850 per year after Amgen's voluntary price cuts and rebates 8. Despite those reductions, most insurers require prior authorization and step therapy documentation showing failure of or intolerance to a statin plus ezetimibe.

The Institute for Clinical and Economic Review (ICER) has modeled the cost-effectiveness threshold for PCSK9 inhibitors. At the current net price, evolocumab approaches cost-effectiveness for very high-risk patients (those with recurrent ASCVD events or FH with LDL above 100 mg/dL despite maximized oral therapy) but remains above conventional willingness-to-pay thresholds for moderate-risk patients 5.

A practical strategy many clinicians use: start ezetimibe, recheck LDL at 4 to 6 weeks, and escalate to a PCSK9 inhibitor only if the patient remains substantially above goal. This approach satisfies most prior authorization requirements and avoids unnecessary cost.

Safety: Long-Term Data for Both Drugs

Both ezetimibe and evolocumab have reassuring long-term safety profiles, though the depth of available data differs.

Ezetimibe has more than two decades of post-marketing surveillance. IMPROVE-IT followed patients for a median of 6 years, and no excess risk of cancer, liver injury, or myopathy was observed. Post-hoc analyses showed ezetimibe was safe even in patients who achieved LDL levels below 30 mg/dL in combination with simvastatin 1.

Evolocumab's safety record is shorter but increasingly mature. The FOURIER open-label extension (FOURIER-OLE) followed patients for up to 5 additional years, and there was no increase in neurocognitive events, new-onset diabetes, hemorrhagic stroke, or cataracts 3. The EBBINGHAUS substudy, which used formal neurocognitive testing, found no difference in cognitive function between evolocumab and placebo groups despite median achieved LDL levels of 30 mg/dL 9.

Injection-site reactions occur in roughly 2% of patients receiving evolocumab. These are generally mild. The development of anti-drug antibodies has been rare and has not affected efficacy or safety in published analyses 2.

Neither drug has the myalgia burden that statins carry. This makes both agents especially useful in statin-intolerant patients, though the magnitude of LDL lowering with ezetimibe monotherapy (about 18% to 20%) is modest compared with evolocumab monotherapy (about 55% to 60%) 6.

Emerging Alternatives: Where Inclisiran and Bempedoic Acid Fit

The ezetimibe-vs-PCSK9 decision is no longer binary. Inclisiran (Leqvio), a small interfering RNA that silences PCSK9 production, achieved FDA approval in 2021 and offers twice-yearly dosing administered in-office. The ORION-10 and ORION-11 trials showed LDL reductions of approximately 52%, positioning inclisiran between ezetimibe and evolocumab in potency 10. Cardiovascular outcomes data from ORION-4 (N=15,000, results expected 2026) will clarify whether inclisiran matches evolocumab's event reduction.

Bempedoic acid (Nexletol), an ATP citrate lyase inhibitor, lowers LDL by about 18% on top of a statin and by roughly 24% in statin-intolerant patients. The CLEAR Outcomes trial (N=13,970) showed a 13% relative reduction in four-component MACE (HR 0.87, 95% CI 0.79-0.96, P=0.004), making bempedoic acid the first oral non-statin shown to reduce cardiovascular events in statin-intolerant patients 11.

These newer agents do not replace the ezetimibe-to-PCSK9 inhibitor escalation pathway, but they do provide additional options at each tier of LDL reduction.

The Bottom Line for Clinicians

The 2022 ACC Expert Consensus Decision Pathway specifies a clear sequence: maximize statin dose, add ezetimibe, then add a PCSK9 inhibitor or inclisiran if LDL remains above the patient's risk-based threshold 5. For very high-risk patients (those with a history of multiple MACE events, multivessel coronary disease, or FH with LDL above 100 mg/dL despite oral therapy), the guidelines support earlier use of PCSK9 inhibitors. In FOURIER, each 1 mmol/L (38.7 mg/dL) reduction in LDL with evolocumab reduced the key secondary endpoint by 22%, matching the CTT prediction exactly 2 4. For the patient with moderate LDL elevation above goal on a statin, generic ezetimibe at $15 per month remains the single most cost-effective next step in cardiovascular risk reduction.